Tempus Announces Acquisition of Deep 6 AI
Tempus AI (NASDAQ: TEM) has announced the acquisition of Deep 6 AI, a leading AI-powered precision research platform. Deep 6 AI's network spans over 750 provider site locations and more than 30 million patients, which will significantly expand Tempus' existing infrastructure.
Deep 6 AI specializes in clinical trial optimization, patient recruitment acceleration, and real-world evidence generation. Their AI software matches patients to clinical trials by analyzing real-time structured and unstructured EMR data across various healthcare institutions, including academic medical centers, NCI-Designated Cancer Centers, and NCI Community Oncology Research Programs.
The acquisition aims to enhance Tempus' connectivity efforts and strengthen its ability to deploy critical applications like Next (for closing care gaps) and TIME (for matching patients to clinical trials).
Tempus AI (NASDAQ: TEM) ha annunciato l'acquisizione di Deep 6 AI, una piattaforma di ricerca di precisione basata sull'IA leader nel settore. La rete di Deep 6 AI si estende su oltre 750 sedi di fornitori e più di 30 milioni di pazienti, il che espanderà significativamente l'infrastruttura esistente di Tempus.
Deep 6 AI si specializza nell'ottimizzazione delle sperimentazioni cliniche, nell'accelerazione del reclutamento dei pazienti e nella generazione di evidenze reali. Il loro software di intelligenza artificiale abbina i pazienti alle sperimentazioni cliniche analizzando dati EMR strutturati e non strutturati in tempo reale provenienti da varie istituzioni sanitarie, tra cui centri medici accademici, centri oncologici designati dal NCI e programmi di ricerca oncologica comunitaria del NCI.
L'acquisizione mira a migliorare gli sforzi di connettività di Tempus e a rafforzare la sua capacità di implementare applicazioni critiche come Next (per colmare le lacune nelle cure) e TIME (per abbinare i pazienti alle sperimentazioni cliniche).
Tempus AI (NASDAQ: TEM) ha anunciado la adquisición de Deep 6 AI, una plataforma líder de investigación de precisión impulsada por IA. La red de Deep 6 AI abarca más de 750 ubicaciones de proveedores y más de 30 millones de pacientes, lo que ampliará significativamente la infraestructura existente de Tempus.
Deep 6 AI se especializa en la optimización de ensayos clínicos, la aceleración del reclutamiento de pacientes y la generación de evidencia del mundo real. Su software de IA empareja a los pacientes con ensayos clínicos analizando datos EMR estructurados y no estructurados en tiempo real de diversas instituciones de salud, incluidos centros médicos académicos, centros de cáncer designados por el NCI y programas de investigación oncológica comunitaria del NCI.
La adquisición tiene como objetivo mejorar los esfuerzos de conectividad de Tempus y fortalecer su capacidad para implementar aplicaciones críticas como Next (para cerrar brechas en la atención) y TIME (para emparejar pacientes con ensayos clínicos).
템퍼스 AI (NASDAQ: TEM)는 AI 기반의 정밀 연구 플랫폼인 Deep 6 AI의 인수를 발표했습니다. Deep 6 AI의 네트워크는 750개 이상의 제공자 사이트와 3천만 명 이상의 환자를 아우르며, 이는 템퍼스의 기존 인프라를 크게 확장할 것입니다.
Deep 6 AI는 임상 시험 최적화, 환자 모집 가속화 및 실제 증거 생성에 전문화되어 있습니다. 그들의 AI 소프트웨어는 다양한 의료 기관에서 실시간으로 구조화된 및 비구조화된 EMR 데이터를 분석하여 환자를 임상 시험에 매칭합니다. 여기에는 학술 의료 센터, NCI 지정 암 센터 및 NCI 지역 사회 종양학 연구 프로그램이 포함됩니다.
이번 인수는 템퍼스의 연결 노력 개선과 Next(치료 격차 해소를 위한) 및 TIME(환자를 임상 시험에 매칭하기 위한)와 같은 중요한 애플리케이션을 배포할 수 있는 능력을 강화하는 것을 목표로 합니다.
Tempus AI (NASDAQ: TEM) a annoncé l'acquisition de Deep 6 AI, une plateforme de recherche de précision alimentée par l'IA. Le réseau de Deep 6 AI s'étend sur plus de 750 sites de prestataires et plus de 30 millions de patients, ce qui élargira considérablement l'infrastructure existante de Tempus.
Deep 6 AI se spécialise dans l'optimisation des essais cliniques, l'accélération du recrutement des patients et la génération de preuves du monde réel. Leur logiciel d'IA associe les patients aux essais cliniques en analysant des données EMR structurées et non structurées en temps réel provenant de diverses institutions de santé, y compris des centres médicaux académiques, des centres de cancer désignés par le NCI et des programmes de recherche en oncologie communautaire du NCI.
L'acquisition vise à améliorer les efforts de connectivité de Tempus et à renforcer sa capacité à déployer des applications critiques telles que Next (pour combler les lacunes dans les soins) et TIME (pour associer les patients aux essais cliniques).
Tempus AI (NASDAQ: TEM) hat die Übernahme von Deep 6 AI, einer führenden KI-gestützten Präzisionsforschungsplattform, bekannt gegeben. Das Netzwerk von Deep 6 AI erstreckt sich über mehr als 750 Anbieterstandorte und mehr als 30 Millionen Patienten, was die bestehende Infrastruktur von Tempus erheblich erweitern wird.
Deep 6 AI ist auf die Optimierung klinischer Studien, die Beschleunigung der Patientenrekrutierung und die Generierung von realen Beweisen spezialisiert. Ihre KI-Software verknüpft Patienten mit klinischen Studien, indem sie in Echtzeit strukturierte und unstrukturierte EMR-Daten aus verschiedenen Gesundheitseinrichtungen analysiert, darunter akademische medizinische Zentren, vom NCI designierte Krebszentren und NCI-Programme für Gemeinschafts-Onkologie-Forschung.
Die Übernahme zielt darauf ab, die Konnektivitätsbemühungen von Tempus zu verbessern und die Fähigkeit zu stärken, kritische Anwendungen wie Next (zur Schließung von Versorgungslücken) und TIME (zum Abgleichen von Patienten mit klinischen Studien) bereitzustellen.
- Significant network expansion with 750+ provider locations and 30M+ patient records
- Enhanced clinical trial matching and patient recruitment capabilities
- Strengthened AI infrastructure for precision medicine applications
- Expanded presence in academic and NCI-designated cancer centers
- None.
Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network
Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data across a broad ecosystem, which includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research Programs.
“Deep 6’s impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care for their patients,” said Eric Lefkofsky, Founder and CEO of Tempus. “This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and TIME, which helps patients find potentially life saving clinical trials.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding Tempus’ acquisition of Deep 6 AI, Deep 6 AI’s customer base, and Tempus’s ability to integrate Deep 6’s operations to enhance its existing products. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310060228/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
How many provider locations and patients will Deep 6 AI add to Tempus' network?
What are the main capabilities of Deep 6 AI's platform that TEM is acquiring?
How will the Deep 6 AI acquisition benefit TEM's existing applications?
What types of healthcare institutions are currently in Deep 6 AI's network?
